Immunogenicity, Efficacy and Safety of Treatment With Human-cl-rhFVIII in Previously Untreated Patients With Severe Hemophilia A

Trial Profile

Immunogenicity, Efficacy and Safety of Treatment With Human-cl-rhFVIII in Previously Untreated Patients With Severe Hemophilia A

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 02 Dec 2017

At a glance

  • Drugs Simoctocog alfa (Primary)
  • Indications Haemophilia A
  • Focus Pharmacodynamics; Registrational
  • Acronyms NuProtect
  • Sponsors Octapharma
  • Most Recent Events

    • 23 Aug 2017 Interim results (n=66) published in an Octapharma Media Release.
    • 23 Aug 2017 According to an Octapharma media release, Interim results were published in the medical journal Haemophilia.
    • 10 Jul 2017 Interim results were presented at the International Society on Thrombosis and Haemostasis (ISTH) Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top